Skip to main content

The Sjögren's Foundation is proud to announce our participation in a landmark partnership that will investigate how cells of the immune system interact in tissue to drive inflammation and autoimmune disease.

The Foundation for the National Institutes of Health (FNIH) and the National Institutes of Health (NIH) are launching a new partnership to investigate how cells of the immune system interact in tissue to drive inflammation and autoimmune disease. The Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) Program will advance our understanding of key disease pathways using new tools to map in three-dimensions how cell types, cell states, and cell-to-cell interactions network to cause inflammation, abnormal function, and tissue injury. The resulting data will accelerate our understanding of the fundamental mechanisms and causes of autoimmune disease, allow more informed selection of patients for clinical trials, and generate new targets for drug development.

Janet Church

We are extremely proud to join the AMP AIM project as a Steering Committee member alongside the NIH, other disease advocacy organizations and pharmaceutical companies. AMP AIM offers a new way to tackle the formidable barriers that have prevented us from fully understanding Sjögren’s and will potentially uncover mysteries so we can better diagnose and treat Sjögren’s patients in the future.

Click Here to Read Full FNIH Announcement

Autoimmune diseases affect more than 25 million Americans, and recent studies suggest that the prevalence and incidence of these diseases are increasing. Rheumatoid arthritis (RA), psoriatic spectrum diseases, Sjögren’s disease, and systemic lupus erythematosus (SLE) are chronic autoimmune diseases characterized by profound abnormalities in immune responses that damage multiple tissues and organ systems, often with devastating results. Complex differences in patient genetics and immune function at the cellular level make developing new treatments particularly challenging and complicate patient care. However, many autoimmune diseases share common inflammatory pathways, comorbidity risks, and even responses to disease-modifying therapies. Better tools to define and map these shared and unique immune cell interactions and pathways are critical for the design of new targets and interventions.

AMP AIM is the latest initiative to emerge from the Accelerating Medicines Partnership (AMP) Program, a public-private collaboration among the NIH, the U.S. Food and Drug Administration (FDA), the pharmaceutical industry, and patient organizations to speed drug development across different diseases. AMP AIM brings together the resources of 17 partner organizations spanning the public, private, and nonprofit sectors, with combined commitments totaling over $58.5 million. The FNIH will provide program and project management for the effort over the next five years. 

Click Here to Read Official FNIH Press Release